Skip to main content
Clinical Trials/NCT02635178
NCT02635178
Completed
Not Applicable

Randomized Control Trial Examining a Brief Anxiety Sensitivity Cognitive Concerns Intervention for Obsessive Compulsive Symptoms

Florida State University0 sites72 target enrollmentAugust 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obsessive-Compulsive Disorder and Symptoms
Sponsor
Florida State University
Enrollment
72
Primary Endpoint
Anxiety Sensitivity Index-3 (ASI-3)
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Obsessive-compulsive disorder (OCD), characterized by recurrent obsessions and/or compulsions, is a disabling psychiatric condition affecting approximately 2-3% of the population. Whereas several first-line treatments have been established (e.g., pharmacological and psychological), a substantial proportion of patients (40-60%) fail to experience symptom remission, underscoring the need for research in this area. One approach to increasing treatment efficacy is to target underlying risk factors or dysfunctions that may in turn improve outcomes. One such risk factor is anxiety sensitivity (AS) cognitive concerns. AS cognitive concerns reflects fears of mental incapacitation (e.g., "It scares me when I am unable to keep my mind on a task"). There is recent evidence that AS cognitive concerns is uniquely associated with various obsessive-compulsive (OC) symptom domains. However, questions remain as to whether reductions in AS cognitive concerns will lead to subsequent reductions in OC symptoms. The purpose of the proposed study is to investigate the efficacy of a brief AS cognitive concerns intervention on reductions in OC symptoms.

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
April 2017
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Norman Schmidt

Professor

Florida State University

Eligibility Criteria

Inclusion Criteria

  • Participants must be 18 years of age or older
  • Elevated levels of obsessive-compulsive symptoms as indicated by scoring one standard deviation above the non-clinical mean on any Dimensional Obsessive-Compulsive Scale dimension
  • Elevated anxiety sensitivity cognitive concerns as indicated by scoring one standard deviation above the non-clinical mean

Exclusion Criteria

  • Evidence of a significant medical illness that would prevent the completion of interoceptive exposure (IE) exercises
  • Non-English speakers
  • Individuals currently receiving cognitive-behavioral therapy for anxiety and/or mood disorders or who are not stable on psychotropic medications (i.e., new medication or changes in dosage within the last three months)

Outcomes

Primary Outcomes

Anxiety Sensitivity Index-3 (ASI-3)

Time Frame: Month 1 Follow-Up

The ASI-3 is an 18-item self-report measure of AS. This scale was developed to provide a more stable measure of the three most widely recognized AS subfactors (cognitive, social and physical concerns) than the original ASI provides. The measure has shown good psychometric properties (Taylor et al., 2007).

Secondary Outcomes

  • Sheehan Disability Scale (SDS)(Month 1 Follow-Up)
  • Dimensional Obsessive Compulsive Scale (DOCS)(Month 1 Follow-Up)

Similar Trials